Research from University of London, Imperial College in the area of HIV/AIDS published
2009 JUL 8 - (NewsRx.com) -- "Monocyte-derived dendritic cells (MDDCs) have been used in therapeutic vaccination for cancer. A small number of studies have employed a similar approach to vaccinate human immunodeficiency virus (HIV)-infected individuals," scientists in London, the United Kingdom report. "We have thus analyzed the functional properties of MDDCs generated from HIV-infected individuals who either are receiving highly active antiretroviral therapy or are therapy naive. There was no difference in the MDDC phenotype or efficiency of MDDC generation between HIV-infected individuals and healthy control subjects. Despite this, the MDDCs derived from both groups of infected individuals were severely impaired in their ability to stimulate the proliferation of allogeneic T cells. Furthermore, production of interferon-gamma was reduced in T cells stimulated by MDDCs. These functional changes may be at least partly explained by reduced interleukin-12 and increased interleukin-10 secretion on stimulation with lipopolysaccharide and CD40 ligand," wrote S. Buisson and colleagues, University of London, Imperial College. The researchers concluded: "Our findings suggest that MDDCs used in therapeutic vaccination of HIV-infected individuals may show reduced potency.." Buisson and colleagues published their study in the Journal of Infectious Diseases (Monocyte-Derived Dendritic Cells from HIV Type 1-Infected Individuals Show Reduced Ability to Stimulate T Cells and Have Altered Production of Interleukin (IL)-12 and IL-10. Journal of Infectious Diseases, 2009;199(12):1862-1871). For additional information, contact S. Patterson, University of London Imperial College, Dept. of Immunology, Faculty Medical, Chelsea & Westminster Hospital, 369 Fulham Rd., London SW10 9NH, UK. The publisher's contact information for the Journal of Infectious Diseases is: University Chicago Press, 1427 E 60th St., Chicago, IL 60637-2954, USA. Keywords: United Kingdom, London, HIV/AIDS, AIDS, Acquired Immune Deficiency Syndrome, Acquired Immunodeficiency Syndrome, Antivirals, Cancer, HIV, Human Immunodeficiency Virus, Immunization, Immunology, Oncology, Sexually Transmitted Disease, Therapy, Treatment, Vaccination, Viral, Virology, University of London, Imperial College. This article was prepared by Vaccine Weekly editors from staff and other reports. Copyright 2009, Vaccine Weekly via NewsRx.com.
|
